RecruitingNCT07102043

Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)

Glucose Metabolism in CFRD: Exploring the Role of CFTR Modulators in Metabolic Dysfunction

Sponsor

University of Alabama at Birmingham

Enrollment

30 participants

Start Date

May 28, 2026

Study Type

OBSERVATIONAL

Conditions

Cystic Fibrosis-related Diabetes

Summary

The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR modulator (ETI) therapy (CFRDF508del+ETI). CFRD with a mutation that is not eligible for modulator therapy (CFRD-ETI) will be the control group.

Eligibility

Min Age: 21 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with cystic fibrosis-related diabetes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07102043

Related Trials

FEED-Cystic Fibrosis (FEED-CF)

NCT057667741 location

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

NCT045303831 location